vs
EyePoint, Inc.（EYPT）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是EyePoint, Inc.的5.2倍（$3.2M vs $619.0K）。STANDARD BIOTOOLS INC.净利率更高（598.5% vs -10922.3%，领先11520.8%）。STANDARD BIOTOOLS INC.同比增速更快（262.0% vs -94.7%）。STANDARD BIOTOOLS INC.自由现金流更多（$-1.7M vs $-66.0M）。过去两年STANDARD BIOTOOLS INC.的营收复合增速更高（-73.4% vs -77.0%）
EyePoint制药公司总部位于马萨诸塞州沃特敦，是一家专注于将微机电系统（MEMS）与纳米技术应用于给药领域的专业医药企业，依托前沿交叉技术开发创新给药方案，聚焦眼科等领域的药物递送技术创新与产品开发。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
EYPT vs LAB — 直观对比
营收规模更大
LAB
是对方的5.2倍
$619.0K
营收增速更快
LAB
高出356.7%
-94.7%
净利率更高
LAB
高出11520.8%
-10922.3%
自由现金流更多
LAB
多$64.4M
$-66.0M
两年增速更快
LAB
近两年复合增速
-77.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $619.0K | $3.2M |
| 净利润 | $-67.6M | $19.3M |
| 毛利率 | — | 83.5% |
| 营业利润率 | -11364.3% | -578.6% |
| 净利率 | -10922.3% | 598.5% |
| 营收同比 | -94.7% | 262.0% |
| 净利润同比 | -63.3% | 156.6% |
| 每股收益（稀释后） | $-0.82 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EYPTLAB
| Q4 25 | $619.0K | $3.2M | ||
| Q3 25 | $966.0K | $19.6M | ||
| Q2 25 | $5.3M | $21.8M | ||
| Q1 25 | $24.5M | $40.8M | ||
| Q4 24 | $11.6M | $890.0K | ||
| Q3 24 | $10.5M | $22.1M | ||
| Q2 24 | $9.5M | $22.5M | ||
| Q1 24 | $11.7M | $45.5M |
净利润EYPTLAB
| Q4 25 | $-67.6M | $19.3M | ||
| Q3 25 | $-59.7M | $-34.7M | ||
| Q2 25 | $-59.4M | $-33.5M | ||
| Q1 25 | $-45.2M | $-26.0M | ||
| Q4 24 | $-41.4M | $-34.1M | ||
| Q3 24 | $-29.4M | $-26.9M | ||
| Q2 24 | $-30.8M | $-45.7M | ||
| Q1 24 | $-29.3M | $-32.2M |
毛利率EYPTLAB
| Q4 25 | — | 83.5% | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | -202.8% | ||
| Q3 24 | 93.0% | 54.9% | ||
| Q2 24 | 85.2% | 46.1% | ||
| Q1 24 | 93.5% | 53.1% |
营业利润率EYPTLAB
| Q4 25 | -11364.3% | -578.6% | ||
| Q3 25 | -6420.8% | -168.5% | ||
| Q2 25 | -1166.8% | -118.1% | ||
| Q1 25 | -199.7% | -80.8% | ||
| Q4 24 | -390.4% | -1162.1% | ||
| Q3 24 | -311.2% | -120.9% | ||
| Q2 24 | -364.5% | -134.5% | ||
| Q1 24 | -285.2% | -132.2% |
净利率EYPTLAB
| Q4 25 | -10922.3% | 598.5% | ||
| Q3 25 | -6183.4% | -177.4% | ||
| Q2 25 | -1114.3% | -153.7% | ||
| Q1 25 | -184.8% | -63.8% | ||
| Q4 24 | -357.3% | -3828.3% | ||
| Q3 24 | -279.0% | -122.0% | ||
| Q2 24 | -325.3% | -203.3% | ||
| Q1 24 | -250.6% | -70.6% |
每股收益（稀释后）EYPTLAB
| Q4 25 | $-0.82 | $0.05 | ||
| Q3 25 | $-0.85 | $-0.09 | ||
| Q2 25 | $-0.85 | $-0.09 | ||
| Q1 25 | $-0.65 | $-0.07 | ||
| Q4 24 | $-0.65 | $-0.06 | ||
| Q3 24 | $-0.54 | $-0.07 | ||
| Q2 24 | $-0.58 | $-0.12 | ||
| Q1 24 | $-0.55 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $306.1M | $120.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $306.1M | $424.3M |
| 总资产 | $364.0M | $567.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EYPTLAB
| Q4 25 | $306.1M | $120.9M | ||
| Q3 25 | $204.0M | $129.4M | ||
| Q2 25 | $255.7M | $158.6M | ||
| Q1 25 | $318.2M | $150.9M | ||
| Q4 24 | $370.9M | $166.7M | ||
| Q3 24 | $253.8M | $210.6M | ||
| Q2 24 | $280.2M | $269.8M | ||
| Q1 24 | $299.3M | $287.1M |
总债务EYPTLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $299.0K | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益EYPTLAB
| Q4 25 | $306.1M | $424.3M | ||
| Q3 25 | $200.2M | $399.7M | ||
| Q2 25 | $246.0M | $424.5M | ||
| Q1 25 | $298.4M | $454.6M | ||
| Q4 24 | $336.5M | $471.7M | ||
| Q3 24 | $218.7M | $489.3M | ||
| Q2 24 | $228.3M | $510.3M | ||
| Q1 24 | $249.9M | $577.3M |
总资产EYPTLAB
| Q4 25 | $364.0M | $567.8M | ||
| Q3 25 | $251.7M | $539.6M | ||
| Q2 25 | $301.1M | $557.0M | ||
| Q1 25 | $362.6M | $579.6M | ||
| Q4 24 | $418.5M | $612.3M | ||
| Q3 24 | $300.9M | $681.5M | ||
| Q2 24 | $324.2M | $708.7M | ||
| Q1 24 | $329.2M | $777.7M |
负债/权益比EYPTLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-65.0M | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | $-66.0M | $-1.7M |
| 自由现金流率自由现金流/营收 | -10667.7% | -51.7% |
| 资本支出强度资本支出/营收 | 159.3% | 14.8% |
| 现金转化率经营现金流/净利润 | — | -0.06× |
| 过去12个月自由现金流最近4个季度 | $-243.4M | $-82.6M |
8季度趋势，按日历期对齐
经营现金流EYPTLAB
| Q4 25 | $-65.0M | $-1.2M | ||
| Q3 25 | $-59.4M | $-22.2M | ||
| Q2 25 | $-62.6M | $-20.7M | ||
| Q1 25 | $-53.1M | $-30.3M | ||
| Q4 24 | $-35.8M | $-14.1M | ||
| Q3 24 | $-39.0M | $-27.9M | ||
| Q2 24 | $-20.2M | $-39.0M | ||
| Q1 24 | $-31.2M | $-62.5M |
自由现金流EYPTLAB
| Q4 25 | $-66.0M | $-1.7M | ||
| Q3 25 | $-60.2M | $-23.1M | ||
| Q2 25 | $-63.8M | $-22.6M | ||
| Q1 25 | $-53.4M | $-35.3M | ||
| Q4 24 | $-36.2M | $-17.4M | ||
| Q3 24 | $-40.6M | $-30.1M | ||
| Q2 24 | $-21.1M | $-41.0M | ||
| Q1 24 | $-32.4M | $-63.3M |
自由现金流率EYPTLAB
| Q4 25 | -10667.7% | -51.7% | ||
| Q3 25 | -6226.9% | -118.1% | ||
| Q2 25 | -1196.5% | -103.6% | ||
| Q1 25 | -218.4% | -86.6% | ||
| Q4 24 | -312.7% | -1959.7% | ||
| Q3 24 | -385.8% | -136.4% | ||
| Q2 24 | -222.4% | -182.2% | ||
| Q1 24 | -277.0% | -138.9% |
资本支出强度EYPTLAB
| Q4 25 | 159.3% | 14.8% | ||
| Q3 25 | 82.6% | 4.5% | ||
| Q2 25 | 22.9% | 8.7% | ||
| Q1 25 | 1.1% | 12.4% | ||
| Q4 24 | 3.3% | 380.0% | ||
| Q3 24 | 15.0% | 10.2% | ||
| Q2 24 | 9.5% | 8.6% | ||
| Q1 24 | 10.2% | 1.7% |
现金转化率EYPTLAB
| Q4 25 | — | -0.06× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
